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Model organisms contribute to diagnosis
and discovery in the undiagnosed diseases
network: current state and a future vision
Dustin Baldridge1*† , Michael F. Wangler2,3,4,5*†, Angela N. Bowman6,7, Shinya Yamamoto2,4,5,8 , Undiagnosed
Diseases Network, Tim Schedl7,9, Stephen C. Pak1, John H. Postlethwait10, Jimann Shin6, Lilianna Solnica‑Krezel6,7,
Hugo J. Bellen2,4,5,8,11 and Monte Westerfield10

Abstract
Decreased sequencing costs have led to an explosion of genetic and genomic data. These data have revealed thou‑
sands of candidate human disease variants. Establishing which variants cause phenotypes and diseases, however, has
remained challenging. Significant progress has been made, including advances by the National Institutes of Health
(NIH)-funded Undiagnosed Diseases Network (UDN). However, 6000–13,000 additional disease genes remain to be
identified. The continued discovery of rare diseases and their genetic underpinnings provides benefits to affected
patients, of whom there are more than 400 million worldwide, and also advances understanding the mechanisms of
more common diseases. Platforms employing model organisms enable discovery of novel gene-disease relationships,
help establish variant pathogenicity, and often lead to the exploration of underlying mechanisms of pathophysiology
that suggest new therapies. The Model Organism Screening Center (MOSC) of the UDN is a unique resource dedi‑
cated to utilizing informatics and functional studies in model organisms, including worm (Caenorhabditis elegans), fly
(Drosophila melanogaster), and zebrafish (Danio rerio), to aid in diagnosis. The MOSC has directly contributed to the
diagnosis of challenging cases, including multiple patients with complex, multi-organ phenotypes. In addition, the
MOSC provides a framework for how basic scientists and clinicians can collaborate to drive diagnoses. Customized
experimental plans take into account patient presentations, specific genes and variant(s), and appropriateness of each
model organism for analysis. The MOSC also generates bioinformatic and experimental tools and reagents for the
wider scientific community. Two elements of the MOSC that have been instrumental in its success are (1) multidiscipli‑
nary teams with expertise in variant bioinformatics and in human and model organism genetics, and (2) mechanisms
for ongoing communication with clinical teams. Here we provide a position statement regarding the central role of
model organisms for continued discovery of disease genes, and we advocate for the continuation and expansion of
MOSC-type research entities as a Model Organisms Network (MON) to be funded through grant applications submit‑
ted to the NIH, family groups focused on specific rare diseases, other philanthropic organizations, industry partner‑
ships, and other sources of support.
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The future of human genetics
Even though the human genome was sequenced in 2003,
the era of functional genomics is just beginning. The
deployment of next-generation sequencing revealed a
staggering number of variants across individuals, with
each human genome containing an average of more than
3 million single nucleotide variants when compared
to the reference sequence [1, 2]. Of the approximately
20,000 human genes, only ~ 4000 are currently linked to
monogenic disease and/or rare disease in Online Mendelian Inheritance in Man (OMIM) [3, 4] and Orphanet [5].
Importantly, although a single rare disease might
impact only a few individuals, as a whole, rare diseases
affect up to 25 million people in the US alone according
to the Centers for Disease Control and Prevention (CDC)
[6]. Bamshad et al. proposed that there are 6000–13,000
additional disease genes that remain to be identified for
Mendelian traits and rare diseases [7]. Thus, disease gene
discovery will continue for many years.
Patients with rare diseases typically have long, expensive, and frustrating diagnostic odysseys, and research
with model organisms can significantly shorten their
journeys by identifying causative genetic variants and
disease mechanisms. The major goal of the NIH-funded
MOSC, as an essential component of the UDN, is to provide experimental results to help evaluate a diagnosis,
thus concluding the diagnostic odyssey. Such genetic discovery efforts typically lead to the identification of new
disease genes. Although uncovering the genetic underpinnings of rare diseases for diagnosis has inherent value
(e.g., for reproductive planning), it also provides significant opportunities to study rare disease biology. Such
findings can contribute to a better understanding of basic
biological systems and pathways, leading to development
of treatments and cures and linking rare conditions with
more common disease mechanisms [8, 9].
The value of model organism screening centers
The purpose of the MOSC is to use genetic approaches
in non-mammalian model organisms to evaluate the
hypothesis that specific genes and variants identified in
patients enrolled in the UDN are likely to cause patient
clinical phenotypes. The UDN is an NIH Common Fund
program arising from the earlier intramural NIH Undiagnosed Diseases Program (UDP), and now consists of a
network of academic medical centers dedicated to solving medical mysteries [10]. Through the use of in-depth
clinical evaluations and exome or genome sequencing
and analysis, numerous patients with challenging and

medically complex conditions are able to obtain a molecular diagnosis through participation in the UDN [11].
In many cases, the identification of an ‘n = 1’ potentially
pathogenic variant from sequencing alone does not provide sufficient evidence that the variant is indeed causative. A subset of these cases may be solved by identifying
several similarly affected patients who harbor putative
pathogenic variants in the same gene, a process that is
facilitated by platforms like the Matchmaker Exchange
[12]. Unfortunately, this process is costly, slow, and frequently unsuccessful. Therefore, due to the recurring
need for functional assessment of putative pathogenic
variants, the UDN established the MOSC during Phase
I of the program (September 2015 to August 2018), and
expanded the MOSC in Phase II (September 2018–July
2022) [13].
The initial MOSC structure included a bioinformatics component, a Drosophila melanogaster (Drosophila;
Fly) Core, and a Zebrafish Core. We note that the term
“Center” is used for the overall structure of the MOSC,
and the term “Core” is used for individual model organism teams due to the administrative structure specified in
the NIH funding opportunity announcement. However,
activities conducted by the MOSC Cores are significantly
more advanced than those typically conducted by traditional research core facilities. The bioinformatics component analyzes specific genes and variants submitted,
including the use of public databases of “control” individuals with respect to monogenic disease, such as ExAC
and gnomAD [14, 15], and Mendelian disease databases,
such as the Centers for Mendelian Genomics (CMG), to
look for matching cases and variants [4, 12, 16]. These
searches are integrated with specific searches throughout
the literature and across model organism, gene, protein,
and protein structure databases to identify tools and reagents available for potential studies in a given organism.
Based on the vast amount of time spent on bioinformatic
searches and the need for computational tools to help
prioritize model organism studies, the Phase I MOSC
developed a robust integrated platform called MARRVEL
(Model organism Aggregated Resources for Rare Variant
ExpLoration; http://marrvel.org/) that is freely available
online and now widely used [17]. MARRVEL supports
integration of more than 20 online database searches into
a single search [18, 19].
Through extensive model organism studies and the use
of MARRVEL, the MOSC provided key contributions
and new scientific insights during Phase I of the UDN.
During this period, 239 variants in 183 genes from 122
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UDN probands were submitted to the MOSC (Fig. 1).
Of these, 59 genes were studied in the Fly Core and 16 in
the Zebrafish Core, including two genes studied in both
cores. The Phase I MOSC provided in-depth biological
data for 19 genes that led directly to diagnosis (Table 1),
with studies for additional genes ongoing. These discoveries included novel gene discoveries, phenotypic expansions, new biological insights, novel therapeutic targets,
the ability to solve cases with only 1 or 2 patients, and
extrapolation of rare undiagnosed disease mechanisms to
common diseases [20].
The success of the Phase I MOSC led to an expansion in
Phase II with an allocation of additional UDN resources
to functional studies. The current MOSC incorporates
a Worm (C. elegans) Core, a Fly (Drosophila) Core, and
two Zebrafish Cores. The current MOSC uses a two-step
evaluation system: an initial review process to screen
variants primarily based on human genetics information,
followed by Core level reviews to evaluate their appropriateness for specific model organism studies. As of
December 2020, the Phase II MOSC has processed 143
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variants in 109 genes for 108 UDN cases and assigned 60
genes for modeling in one of the three model organisms.

MOSC discovery—historical outcomes and costs
Table 1 lists gene discoveries from the UDN MOSC in
chronological order of publication and illustrates the
breadth of disease phenotypes investigated. Each discovery has the potential to change medicine for that individual gene, disease, and patient and provides direct benefits
outlined below. Estimating costs for each discovery is
challenging due to wide variability from case to case, but
based on Phase I data, an effort like the MOSC can be
expected to deliver approximately six high impact gene
discoveries per year for $900,000 total, or $150,000 per
gene discovery. This estimate accounts for the cost associated with the discovery itself, as well as studies of other
candidate disease genes for patients. Note that some
efforts do not lead to diagnosis and discovery; for example, because each case typically has multiple candidate
genes but typically only one is studied, failure to reveal
a phenotype in a model organism may be due to study of

Fig. 1 Overview of Phase I activity of the Model Organism Screening Center (MOSC) of the Undiagnosed Diseases Network (UDN). A total of 239
variants were submitted for consideration from the 907 cases evaluated at Phase I UDN Clinical Sites. States with Phase I Clinical Sites are marked
in red. After bioinformatic analysis on all submissions, 59 genes were selected for study by the Fly Core and 16 genes by the Zebrafish Core.
Gene names in red indicate novel disease gene candidates, whereas those in black represent proposed phenotypic expansions, according to the
assessment by the clinical sites at the time of submission to the MOSC. Gene names that are in bold and underlined indicate cases where data from
the MOSC directly led to a diagnosis (see Table 1 for details)
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Table 1 UDN MOSC diagnoses and gene discoveries
Disease gene

Disease phenotype

OMIM#

Publication

EBF3

Hypotonia, ataxia, and delayed development syndrome

#617330

[21]

NACC1

Neurodevelopmental disorder with epilepsy, cataracts, feeding difficulties, and delayed brain myelination

#617393

[22]

CACNA1A

Infantile developmental delay, ataxia

N/A

[23]

ATP5F1D

Mitochondrial complex V (ATP synthase) deficiency

#618120

[24]

TBX2

Vertebral anomalies and variable endocrine and T-cell dysfunction

#618223

[25]

IRF2BPL

Neurodevelopmental disorder with regression, abnormal movements, loss of speech, and seizures

#618088

[26]

NR5A1

46, XX sex reversal

#617480

[11]

COG4

Saul-Wilson Syndrome

#618150

[27]

TONSL

Spondyloepimetaphyseal dysplasia, sponastrime type

#271510

[28]

WDR37

Neurooculocardio-genitourinary syndrome

#618652

[29]

ACOX1

Schwann cell and axonal loss

#618960

[30]

TOMM70*

Hypotonia, hyperreflexia, ataxia, dystonia, and white matter abnormalities

N/A

[31]

CDK19*

Epileptic encephalopathy

#618916

[32]

YPEL3

Cerebral hypomyelination, abnormal peripheral nerve conduction, hypotonia, areflexia, and hypertrophic
peripheral nerves

N/A

[33]

BICRA

Neurodevelopmental disorder with intellectual disability, autism, and dysmorphic facial features

N/A

[34]

COPB2

Osteoporosis, fractures, and developmental delay

N/A

[35]

RNF2

Intellectual disability, seizures, and dysmorphic features

N/A

[36]

Additional genes (manuscripts submitted or in preparation) include DROSHA, GDF11, MRTFB*, RAB5B*, SEC24C*, TMEM208*, and TNPO2*
*

Cases submitted during Phase II of the UDN

a candidate that was not the causal gene. We note that
a team-based approach increases the efficiency and lowers the cost of gene discovery through optimization of
resource allocation and avoiding duplication of effort.
In addition to providing evidence that supports diagnoses, the MOSC also generates tools of significant value
for further studies, such as the bioinformatic MARRVEL
platform [17] and valuable in vivo reagents for the scientific community. This includes model organism mutants
with loss of function alleles, lines with the patient
variant(s) knocked into the endogenous gene, and tools
to exogenously express human cDNA. The MOSC makes
research organism reagents available to the international
scientific community through NIH-supported public
stock centers (Caenorhabditis Genetics Center, https://
cgc.umn.edu; Bloomington Drosophila Stock Center,
https://bdsc.indiana.edu; the Drosophila Genomics
Research Center, dgrc.bio.indiana.edu; Zebrafish International Resource Center, https://zebrafish.org) so that they
can be used for further diagnoses, in-depth mechanistic
studies, and proof-of-concept translational and preclinical trial experiments.

Benefits of undiagnosed disease gene discovery
in general
Although the main goal of the UDN is to provide a diagnosis, disease gene discovery also contributes significantly to the lives of patients and their families. Gene

discovery helps by: (1) ending the “diagnostic odyssey”
of individual patients, reducing unnecessary diagnostic
tests, offering prenatal diagnosis options for some families, and improving medical care for individual patients;
(2) leading to diagnoses for patients outside of the UDN
as diagnostic laboratories incorporate published new disease gene discoveries, including those from the UDN,
into their sequencing interpretation and reanalysis processes; (3) facilitating the formation of social media
groups, including family advocacy and support organizations that arise from the more precise molecular diagnoses; (4) enabling the future development of precision
therapies that target the underlying molecular basis of
rare genetic disorders and more common diseases, and
(5) driving an interest in and a positive public perception of genomic research for human health, leading to
greater public interest and understanding of genomics
and rare and undiagnosed disease. While there is clear
economic value to the patient and family members that
have received a diagnosis based on functional studies
performed by the MOSC, it is extremely difficult, if not
impossible, to calculate the precise value of these benefits. Achieving a diagnosis prevents the added expenses
for patients who would have sought evaluation from
additional specialists until they get an answer, and such
answers may not be found for many more years in the
future if the patient’s condition is novel. In addition, the
work by the MOSC has value beyond the individual UDN
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patient or family because the new disease gene discoveries and phenotypic expansions discovered by the MOSC
(Table 1) accelerate diagnoses of patients that are not
part of the UDN but who have the same genetic condition, thereby reducing costs for many families and third
party payers.

Benefits of the existing MOSC structure
The MOSC has been a productive center, and its existing structure provides an efficient mechanism for validation and further characterization of disease genes
and variants using model organisms. In contrast, private companies, even those few that produce model
organism reagents, do not offer model organism

phenotyping. They also do not generally collaborate
directly with clinicians, typically because these commercial laboratories do not have the collective expertise needed. Distributing work across model organism
laboratories requires a central effort to organize and
coordinate activities as well as frequent and open communication among the Model Organism Cores. For
example, review of the clinical phenotype can have an
impact on which model organism laboratory is best
suited to study particular phenotypes or genetic pathways. The two key aspects of (1) multidisciplinary
teams (Fig. 2 and Table 2) and (2) collaborative communication contribute to the high rate of gene discovery
by the MOSC.

Model Organism Screening Center (MOSC)
Submission

Quality
Control

Bioinformatics
Core-level analysis
and assignment

Model Organism Cores
Experimental analysis
Functional information

Clinical
Sites
Inform
Research

Inform
Diagnoses

Fig. 2 Schematic of the relationships among teams that make up the Model Organism Screening Center (MOSC). Functions of the MOSC and
Clinical Sites are noted in blue. Arrows symbolize the collaborative communication among teams

Table 2 Descriptions of Model Organism Screening Center (MOSC) teams
Clinical site teams

Source of candidate genes/variants; provide analysis of high-quality sequencing data in a clinical con‑
text and patient genetic and phenotypic findings

Bioinformatics team

Provides initial quality control based on human genetics, and integrates efforts from each Model
Organism Core to understand evolutionarily relationships (e.g. homology and conserved synteny),
known functions of candidate genes, protein structure and function, integration of information from
model organism databases, availability of reagents, and previously generated knowledge of genes in
models

Worm core team

Expertise in applying C. elegans genetics to the specific genes and variants from undiagnosed patients

Fly core team

Expertise in using Drosophila technology for the specific genes and variants from undiagnosed patients

Fish core team

Expertise in utilizing zebrafish genetics for the specific genes and variants from undiagnosed patients
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Table 3 Evaluating priorities for cases and situations that are relatively higher or lower priority for consideration by the current UDN
MOSC
Higher priority cases

Lower priority cases

1. Unsolved cases
2. Novel candidate disease-causing genes
3. Potential phenotype expansions (novel vari‑
ants in known disease-causing genes, but
with unique phenotypes)

1. Potential complex multi-gene interactions
1. Developing treatment or performing drug
including large copy number variants
screens
2. Somatic or mosaic variation or risk alleles with 2. Generating models for known genetic disor‑
low penetrance
ders
3. Suspected environmental triggers
3. Genes that are not feasible with available tools
4. Potentially solved cases, including variants
or are cost prohibitive, such as those with no
of uncertain significance (VUS) in known
worm ortholog, human cDNA not available for
disease-causing genes with a phenotype
fly, and duplicated genes in zebrafish
match

A multidisciplinary team effort is the first and most
important factor for success, because this collaboration
brings together many groups spanning different areas of
biological science. These benefits include: (1) bridging
clinical/medical terms and model organism jargon, (2)
coming to a consensus on the current understanding of
the genes of interest in the context of medical genetics
and model organism genetics, (3) understanding genome
sequence analysis and potential pitfalls associated with
DNA testing, and (4) having the unique expertise needed
to develop and characterize model organism reagents
that are robust and reliable to produce data relevant to
the patient.
Collaboration and frequent bidirectional communication (represented by arrows in Fig. 2) is the second key
feature of the MOSC. The MOSC uses a centralized
system for some aspects of communication, called the
UDN Gateway, which is an online system developed by
the UDN Coordinating Center to facilitate data sharing
and communication. The current MOSC relies on a network of expert clinical centers that are actively engaged
in rare and undiagnosed diseases research, and whose
participation is essential for the MOSC discovery process. Clinicians at the UDN Clinical Sites provide clinical
information about the participant, explain the rationale
for prioritizing candidate genes and variants that may
contribute to disease phenotypes, and submit one to five
genes/variants per case for further consideration. Clinical Sites submit variants to the MOSC via a built-in feature in the Gateway. Clinical sites and the MOSC teams
attend a monthly call of the Model Organisms Working
Group (MOWG), which facilitates communication about
submissions, expected phenotypes, and model organism assignments. The MOSC also returns decisions via
the Gateway to the Clinical Sites, including which model
organism is appropriate for studying a specific variant,
and eventually, results from model organism studies.
One of the key bidirectional communications is
the interaction between Clinical Sites and the MOSC
Bioinformatics Team. When Clinical Sites submit

Situations currently beyond the scope

candidate variants to the Bioinformatics Team, the latter requests any additional necessary information from
the Clinical Site to assess whether the gene/variant candidates are likely to be the cause of the disease before
the submissions are passed on to informatics teams of
each Model Organism Core. The Bioinformatics Team
communicates the results of variant assessments and
returns variants that are not appropriate for MOSC
model organism work to the Clinical Site. The MOSC
has a wide variety of genetic tools, but there are nonetheless specific variant types that are difficult to tackle
using model organisms (Table 3). Currently, complex
multigene interactions and environmental triggers are
considered lower priority due to the scale of experimental approach that would be required to test these
hypotheses. However, it is possible that new tools and
resources generated in the future could be incorporated to assess these proposed mechanisms of disease
in model organisms.
Another important set of interactions occur among
the MOSC Bioinformatics Team, the Model Organism
Cores, and the Clinical Sites. The information from the
Clinical Sites and the bioinformatics analysis are communicated to the Cores, and in a further step, model
organism experts evaluate each variant in the context of
their specific model, leading to proposals for experimental work. The Bioinformatics Team and Model Organism Core teams communicate back and forth about the
specific genes including homology, human genetics evidence, and hypothesized genetic mechanisms in preparation for the regular MOWG calls with the Clinical Sites.
In addition, each Model Organism Core communicates
directly with the other Model Organism Cores on a regular basis and during the MOWG calls, which allows the
larger MOSC team as a whole to understand how each
model could potentially contribute to the diagnosis of a
particular undiagnosed patient. It is important to select
the best model on a case-by-case basis, allowing optimization of resources for each case. Determining the Model
Organism Core that is best suited to obtain diagnostic or

Baldridge et al. Orphanet J Rare Dis

(2021) 16:206

biological insight is also part of a bidirectional dialogue
involving the Clinical Sites and the MOSC Bioinformatics Team, as are discussions within and between the
Model Organism Cores during the MOWG calls. Also,
the cores that ultimately begin experiments on a gene
communicate directly with the Clinical Site that submitted the case, so that information from the model can be
conveyed to the clinicians as new data become available
so that action plans can be developed.
In summary, some unique hallmarks of the MOSC
are robust, bidirectional, and open communication, as
well as interdisciplinary collaboration among basic scientists, human geneticists, and clinicians through regular individual meetings and monthly working group
calls. This communication is an essential component of
the MOSC and a key scientific justification for a MOSC
structure. These multiple levels and mechanisms of
communications between individuals in separate scientific fields and with complementary expertise ensure
that everyone understands expectations and progress
in data generation, reducing inefficiencies and potential work at cross-purposes. Beyond the UDN, the
MOSC also engages members of other model organism
research communities to apply the benefits of different
models, dovetail efforts, and share best practices. These
features could not be provided if the teams and lines of
communication outlined above did not exist. In conclusion, this effort embodies a truly collaborative spirit.

Benefits of the bioinformatic efforts of the MOSC
A robust system of informatics for quality control of
potential variants is integral to MOSC operations and
discoveries. In the current phase of the UDN, we have
identified Human Genome Variation Society (HGVS)
nomenclature issues in more than 20% of variants
submitted to the MOSC. Examples include mismatch
between cDNA and genomic coordinates, incorrect
representations of short insertions or deletions, and
mistakes when manually transcribing information from
clinical genetic reports. Even though these submissions
have come from top medical genetics centers, the presence of such a high error rate means that the MOSC
needs a robust system to perform variant analysis and
quality control. A bioinformatics team of integrated
physician scientists, clinicians, bioinformaticians, rare
and undiagnosed diseases researchers, geneticists, and
clinical DNA testing experts facilitate this work. Providing this interdisciplinary resource for clinicians, who
usually do not have model organism expertise, is a costeffective and time-efficient mechanism for assessing
the appropriateness of candidate variants for experimental analysis in each of the model systems available,
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discussed in detail below. The current system involves
researchers at Baylor College of Medicine, Washington University in St. Louis, and the University of Oregon who analyze variants for (1) variant nomenclature,
(2) minor allele frequencies in public and CMG databases, (3) gene-based metrics and prediction scores
from public genomic resources, such as gnomAD, and
(4) variant-based in silico prediction scores. The bioinformatics team also examines the clinical scenario
as presented by the Clinical Site, studies gene information using OMIM and other databases, and confirms a
shared understanding of the clinical question motivating the proposal for model organism studies. This team
then communicates these data to the Model Organism
Cores for further analysis, and likewise facilitates communication between the Cores and the Clinical Sites.
The MARRVEL resource, discussed above, is a crucial tool designed to provide rapid access to the data
needed to evaluate a candidate gene and variant for
model organism studies, and has saved many hours of
research time by conducting searches using this integrative tool versus separate searches across multiple
databases. Bioinformatic analyses also leverage the Alliance of Genome Resources (AGR) [37], which aims to
catalog human and model organism data, when reviewing model organism gene expression and functional
information.

Benefits of each model organism in the MOSC
The MOSC utilizes the experimental and genetic tools
of three premier genetic model organisms: worm (Caenorhabditis elegans), fly (Drosophila melanogaster),
and zebrafish (Danio rerio). Indeed, numerous Nobel
prizes in Physiology and Medicine have been awarded to
non-mammalian model organism researchers for their
insights into human biology [13, 38]. Recent examples
include Nobel prizes in Physiology and Medicine for
circadian rhythms using fruit flies (2017), innate immunity using flies (2011), RNA interference in worm (2006),
apoptosis in worm (2002), and embryonic development
in flies (1995). Importantly, these are awards for contributions to medicine resulted directly from model organism studies including those organisms utilized by the
MOSC.
Caenorhabditis elegans (C. elegans, a 1 mm-long nematode worm) is a major research organism for studies of
animal cell and developmental biology [39]. Research in
the worm has provided key insights into human biology
in areas such as apoptosis, cell migration, nervous system wiring, aging, microRNAs, and insulin-like signaling,
because of the conservation of molecular machines (e.g.
spliceosome), intracellular pathways (e.g. autophagy),
intercellular signaling pathways (e.g. Notch signaling),
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and multicellular processes (e.g. basement membrane
biology) across animal biology [40]. The use of C. elegans
in studies of human disease has defined new Mendelian
conditions [41], uncovered phenotypic expansion [42],
and provided the first key mechanistic understanding for
some diseases (e.g., spinal muscular atrophy [43]). The
high efficiency of knocking in patient missense variants
into the orthologous C. elegans gene (which is uniformly
done for the UDN MOSC cases), the short four-day generation time, the large body of acquired knowledge, and
the publicly available biological reagents (WormBase,
https://www.wormbase.org/) facilitate rapid functional
studies of candidate disease gene variants. Such investigations can provide information on the pathogenicity
of the patient variant, evidence in support of the mode
of inheritance including the nature of dominance (e.g.,
antimorph vs. hypermorph), insight into disease mechanisms, and possible routes to treatment.
Drosophila melanogaster (fruit fly) has been used as a
model organism to understand fundamental principles of
genetics, developmental biology, immunity, and neuroscience for the past century [44, 45]. In the last two decades,
Drosophila has become an important model system to
dissect and understand the molecular mechanisms that
underlie human diseases. This is in part because ~ 75%
of human genes shown to cause human diseases were
found to be conserved in Drosophila when the first
genome-wide survey was conducted on ~ 1000 genes
registered in OMIM [46]. Of the ~ 4000 human diseaselinked genes currently displayed in OMIM, ~ 85% have
homologs in flies. Considering that ~ 65% of protein coding genes are conserved between fly and human [17, 47],
the data suggest that genes that are conserved between
these species have a higher likelihood of causing genetic
diseases in human. In addition to being used as a tool to
dissect mechanisms of both common and rare diseases,
and to explore potential therapeutic avenues, the fly has
emerged as a critical tool to interpret variants of uncertain significance found in patients [20]. This is because
state-of-the-art techniques to manipulate the Drosophila
genome allow researchers to engineer flies in many different ways [48–50]. By integrating techniques to knockout, knock-in, knock-down, or overexpress endogenous
and exogenous proteins in a spatiotemporally controlled
manner, fly biologists can quickly unravel the biological
function of a gene of interest in vivo. One can further test
whether the function of the gene is conserved between
flies and human through gene-replacement experiments
in which the human cDNA is used to functionally rescue
loss-of-function alleles of the fly gene. In this paradigm,
the ability of the human reference cDNA to rescue the
fly mutations allows the testing of variants from undiagnosed patients in a relatively short (~ 6 months) time
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frame [44]. Detailed description and discussion of these
strategies employed by the UDN MOSC fly core can be
found in Bellen et al. [20]. All of this work is made possible due to rich public resources that support fly research,
including a centralized database that actively collects and
curates the literature (FlyBase, http://flybase.org/), public stock centers that distribute > 80,000 different strains
of flies (Bloomington Drosophila Stock Center, https://
bdsc.indiana.edu) and > 1,000,000 DNA clones (Drosophila Genomics Resource Center, https://dgrc.bio.
indiana.edu/) supported by the NIH. Genes and variants
found in an undiagnosed patient that are confirmed to
be deleterious can be further studied in flies to identify
disease mechanisms or test FDA-approved drugs that
may be beneficial for the patient through high-throughput screens. This approach has already been effective in
identifying several personalized treatments that can be
returned to the bedside in a short timeframe [9, 32, 51].
The zebrafish (Danio rerio) has emerged as a premier
organism to study human biology [52]. Being a vertebrate, zebrafish have almost all of the same organs and
systems as humans, but are much smaller and develop
much faster, thus supporting rapid studies at organismal,
cellular, and subcellular resolution. Powerful techniques
allow efficient generation, recovery, and analysis of mutations affecting genes that regulate developmental patterning, organogenesis, physiology, and behavior. It is easy
to study gene function by injecting synthetic RNAs into
early zebrafish embryos, generating transgenic zebrafish,
or by altering gene function with genome editing technologies, such as the CRISPR/Cas9 system [53, 54]. The
genome has been sequenced, and 71% of all human genes
and 82% of human-disease related genes have zebrafish
orthologs [55]. Targeted gene knock-out technology is
robust and is the most frequent approach used by the
UDN MOSC fish core, although some patient-specific
knock-in models have also been generated. Further,
studying zebrafish duplicates of human genes facilitates
dissection of multi-function genes due to the evolutionary process of sub-functionalization that occurred after
the teleost genome duplication [56, 57]. Advanced public resources facilitate these increasingly sophisticated
experimental approaches in zebrafish, including a centralized database that actively collects and curates the
literature (The Zebrafish Information Network, http://
zfin.org) and public stock centers that distribute mutant
and transgenic zebrafish strains and molecular reagents
(The Zebrafish International Resource Center, https://
zebrafish.org), both of which are supported by the
NIH. Because organs, cell types, and gene functions are
well conserved across vertebrates, analysis of zebrafish
mutants provides insights into gene functions in other
vertebrates, including humans [58, 59]. Zebrafish are
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used widely to validate candidate human disease genes
and elucidate the molecular mechanisms and pathophysiology of disease [27, 28, 33, 60–62] as well as for drug
discovery [63].
Often the tissue or organismal phenotype studied
in worm or fly, and occasionally in zebrafish, does not
resemble the phenotype of disruption of the orthologous
human gene. Nevertheless, variant-induced dysfunction and genetic mechanisms can be assessed in model
organisms because underlying molecular, cell biological, and genetic pathways are conserved. The term ‘phenolog’ stands for orthologous phenotypes and has been
used when different phenotypes are observed from the
disruption of orthologous genes [64], which occurs due
to diverged organismal biology of the different species.
Two examples of the use of phenologs in gene-variant
assessment are wing defects in flies versus aortic abnormalities in humans, which both involve disrupted Notch
signaling [65] and egg laying defects in worm versus
craniosynostosis in humans caused by missense variants in Twist family genes [41]. The rapid assessment of
the relevant phenolog for a missense variant in worms or
flies provides functional information supporting a timely
diagnosis. It also provides a simple phenotypic readout
to dissect the underlying pathogenic genetic mechanism
and supports the utility of more involved studies of cell
and molecular mechanism.
The MOSC considers multiple factors when determining which model organism is most appropriate
for a UDN case, including gene and variant evolutionary conservation and availability of reagents. If multiple organisms are appropriate for a single case, then the
MOSC generally recommends only the simplest and
fastest model organism in order to maximize the use of
limited resources and to provide information to aid in a
diagnosis as quickly as possible. The worm and fly lineage diverged from the human lineage before the fish and
human lineages diverged, but these invertebrates allow
rapid functional characterization of variants of interests
and further probe into molecular mechanisms of disease. In some situations where clinical phenotypes relate
to vertebrate-specific organs or cell types, zebrafish may
be preferred and recommended. Another consideration
is whether the proposed variant is a missense or protein truncating variant, which is straight forward for all
models, or whether a patient-specific knock-in is necessary which is much more rapid in worms and flies. These
decisions can be quite complex and require extensive
communication among the specific Model Organism
Cores and the Clinical Sites to weigh competing issues
so that all parties can have a shared understanding of the
organism-specific benefits and limitations of the proposed experimental work as well as the intended goal of
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the studies. In summary, the overall endeavor of undiagnosed disease gene discovery, the structure and multidisciplinary nature of the MOSC, and each of the Model
Organism Cores all contribute to the successful diagnosis
of undiagnosed patients.

Vision for the future: proposal for a model
organisms network (MON, formerly MOSC)
We propose sustaining and updating the MOSC through
the creation of a Model Organisms Network (MON),
which would include: (1) a central MOSC-like structure
that is focused on providing functional information for
timely diagnosis, and (2) deep mechanistic studies that
extend to a larger network of researchers.
For (1), a MOSC-like structure, we envision continuation of a multidisciplinary central MON team, including
the communication elements detailed above. We note
that such an effort may extend beyond the needs or priorities of any single NIH institute or center, in keeping
with the observation that most undiagnosed patients
are medically complex and have multiple organ systems
affected, and that undiagnosed diseases afflict both
children and adults. This funding model would sustain
and expand a team and system with similar concepts,
structures, and components as the current MOSC,
but would also integrate additional specialists in the
model organism research field who have the expertise
to pursue mechanistic and translational studies related
to newly discovered disease genes or specific clinical
phenotypes. In addition, we envision the central MON
could garner additional support from philanthropy and
rare disease family groups to fund mechanistic studies
that not only extend and deepen discoveries from currently NIH-funded gene discovery programs like the
UDN and Centers for Mendelian Genomics (CMG), but
also include the many other historically identified disease genes where the underlying disease mechanism is
not currently known. These mechanistic studies could
focus on genes under study in the MON and on solving
undiagnosed diseases.
For (2), mechanistic studies, we envision that studies
by the MON would extend to examining pathways and
therapeutics and constitute “deep dives” into individual genes and variants. Such studies have traditionally
been funded through disparate investigator-initiated ‘R’
grant mechanisms. Although these mechanistic studies
have thus far not been a formal part of the MOSC, they
have been undertaken for some diseases in parallel to
the ongoing diagnosis efforts using alternative funding
sources, including administrative supplements, nonNIH grants, and institutional as well as philanthropic
support [26, 30, 34]. We argue that the future network
needs to balance ongoing disease gene discovery with
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deep mechanistic studies. These mechanistic studies
could leverage the animal disease models and other
tools generated by the MON, and could be undertaken
by any external investigator with a robust approach,
expertise, and reagents for investigating the gene, pathway, and disease uncovered by the MON. We suggest
that these principles could establish a framework that
could inform efforts beyond the current MOSC and
could in principle incorporate other organisms, other
funding mechanisms, and other functional approaches.
We envision that genetic variants will continue to be
submitted by clinicians in various research initiatives
to the future MON and will flow through the following
pipeline: (1) sequencing and bioinformatics, (2) pathogenicity studies in one of the Model Organism Cores,
that includes three organism cores outlined and justified above (diagnosis), and (3) mechanistic studies in
select cases (Fig. 3). The major changes we are proposing from the current MOSC workflow, and which we
describe in more detail below, include the potential for
expanded sources of variant submissions and the interface with deeper mechanistic studies.

Specific components of the proposed MON
Robust teams and communication

The future effort of the MON will require a multidisciplinary team, as well as regular communication, as
exemplified by current MOWG calls and in-person
meetings of the UDN. This process includes the need
for a set of academic clinical centers focused on undiagnosed diseases that continue to study the most
challenging cases and apply state-of-the-art genomic
sequencing technologies to identify candidate variants
for submission to the MON. Other needs are a MON
bioinformatics team familiar with human DNA testing
and sequencing data analysis to ensure quality control,
and, of course, Model Organism Cores with broad biological expertise in the newest genetic technologies in
each organism. Informatics efforts will become even
more important because a future MON could potentially include a wider set of variant sources, leading to a
greater need to harmonize data and assess each variant
with consistent quality control measures.
Variant sources from academic centers with excellence
in undiagnosed diseases

In our vision of the future MON, we foresee an expansion of variant sources beyond the current UDN Clinical
Sites. However, we emphasize that committed academic
centers, such as the current UDN sites, are necessary to ensure successful, high quality clinical evaluations and sequencing, which are the starting points for

Page 10 of 17

identification of candidate disease genes and variants. We
anticipate an ongoing need for timely functional studies; given the estimated 6000–13,000 additional Mendelian disease genes remaining to be identified [7] and the
persistently falling costs of sequencing, patients with
variants in candidate genes will continue to be identified
regularly in the near future. Based on our experience, it
will be necessary to have a certification process to identify sites that follow accepted practices for ensuring high
quality submissions, including both clinical information
and DNA sequences. We also envision that over time,
sites could be educated through training modules, and
that this process could lead to certification of new sites.
Also, as noted above, the participation of experienced
clinical teams actively engaged in identifying patients
with variants in potentially novel disease genes is essential for the success of the MON. In addition to including existing UDN sites, we also propose that sources
of variant submissions for MON analysis be expanded
to include variants proposed by selected entities that
are not presently part of the UDN. One logical choice
would be for the MON to potentially collaborate with
the highly successful NIH-funded CMG [66], and/or the
future Mendelian Genomic Research Centers. The CMG
has made more than 600 novel disease gene discoveries
over the past eight years [66], and the current MOSC has
already been collaborating and publishing with CMG
researchers [23, 67–70]. However, an additional ~ 1200
“Tier 2” genes are not yet definitive disease genes and
these cases would directly benefit from functional evaluation by the MON [66]. In addition, it may be reasonable
for the MON to partner with other groups pursuing gene
discovery for rare and undiagnosed diseases, including
the NIH-funded Rare Diseases Clinical Research Network (RDCRN) [71], as noted below.
MARRVEL and artificial intelligence platforms

Informatic tools provide rapid access to the data needed
to evaluate a candidate gene and variant or model organism studies. The ability of computer-based methods,
including artificial intelligence and deep learning, to
predict the pathogenicity of variants of uncertain significance is likely to improve in coming years. The
MARRVEL resource will continue to expand and add
additional databases, pathogenicity prediction programs,
and widgets to its platform. This type of effort is essential
for the future MON. We envision that the MON will both
support the development of these tools and integrate
them into its workflows as they become robust, to identify appropriate candidate variants efficiently and chose
the most effective model organism for variant validation.
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Fig. 3 Overview of information flow and activities, including original evaluation of the patient and candidate variant identification to model
organism (MO) studies. Outputs include pathogenicity assessment and, in some cases, a “deeper dive” into the underlying mechanism. Proposed
Model Organism Network (MON) activities include identifying disease mechanisms for additional genes through collaborations with other model
organism experts. The red box indicates potential interactions with ongoing gene discovery programs such as the Centers for Mendelian Genomics
(CMG) or its future equivalents

Model organism core teams and additional approaches

Based on the justification above and our past experience, we suggest that, at minimum, the MON will
include Worm, Fly, and Fish Cores following the current structure of the MOSC. These models have proven
the most successful, rapid, and cost-effective for studying undiagnosed diseases and will provide the most
mechanistic insight, given the experience and increasingly sophisticated experimental tools that have
been and are being developed in each system within
a reasonable budget. Although the three proposed
organisms have outstanding ability to model a large
proportion of human variants quickly and inexpensively, cases may exist in which none of the organisms
are suitable, or supplementation with human cell culture studies would provide unique information not possible with worm, fly, or fish. Based on submissions to
the current MOSC, up to 10% of proposed variants in
candidate human disease genes do not have sufficient
evolutionary conservation to be studied in any of the

three MOSC model organisms (especially when including synonymous, intronic or splicing, and UTR variants). In addition, some questions related to specific
cell types affected in the patient might benefit from the
use of patient biopsy or derived cells. The MON should
have ways to incorporate or establish collaborations
that provide mouse models, cellular transfection models, patient derived cells (e.g., fibroblasts), and human
pluripotent stem cell-derived models of relevant cell or
organ types whenever necessary.
The current MOSC does not take direct advantage of
the mouse (Mus musculus) because large-scale functional studies using mice were cost-prohibitive at the
time that the NIH conceived the MOSC idea (~ 2015).
Considering the value of investigations using mice in
the context of rare diseases [72, 73], the MOSC has
been closely working with the Knockout Mouse Phenotyping Program (KOMP2, https://commonfund.nih.
gov/komp2) and International Mouse Phenotyping
consortium (IMPC, https://w ww.mousephenotype.org)
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to leverage the phenotypic data of null mutant animals
in the informatic pipeline for variant prioritization. Due
to rapid advancements in CRISPR-based gene knock-in
and knock-out technologies in mouse and other species
[74, 75], there is no reason for the MON to exclude any
organism that can be genetically manipulated and phenotyped within a reasonable timeframe and cost.
Another complementary approach, but also beyond
the current scope of the MOSC, is the use of patientderived induced pluripotent stem cells (iPSCs), which
can be differentiated into disease-relevant cell types
and organoids to attempt to recapitulate the patient’s
condition [76, 77]. Some current challenges inherent in
the use of iPSCs include the ongoing need to develop
and disseminate standardized differentiation protocols,
the significant cost and time required to generate celltypes of interest, and the high degree of variability that
can be observed from cell line to cell line. If highly reliable and reproducible protocols and functional assays
relevant to the patient’s condition can be established
with reasonable cost and timeline, such approaches will
be highly synergistic with studies carried out in intact
organisms, especially to test genetic variants that lack
model organism orthologs and that are in human-specific non-coding elements.

Challenges to scalability
As we describe above, much progress has been made in
the development of model organism research as a tool for
rare disease gene discovery. However, several challenges
remain before these processes can become scalable and
as easy to execute as some existing fee-for-service tests,
such as exome or genome sequencing. First, disease modeling requires significant understanding of model organism biology and genetics to tailor the experimental design
and analysis to the specific gene, the specific variant(s),
and patient-specific clinical information in the context of
the particular focal research organism. For example, to
uncover a variant-specific disease mechanism, even when
the null phenotype in the model organism is known,
research organism experimental design often must be
modified based on patient genetics, human population
information, the possibility of incomplete penetrance/
expressivity, and the possibility of a gain-of-function or
dominant negative effect. Second, due to these complexities, the bulk of this research requires PhD-level personnel with sufficient expertise and experience to navigate
the existing information, determine feasibilities of the
model organism, design an experimental strategy to support pathogenicity, perform the experiments, and then
bring the discovery to publication. It can be challenging
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to identify qualified research scientists to carry out this
work in a sustainable fashion.

Dual goals of diagnosis and mechanism
We envision NIH support for deep dives into mechanisms that would extend beyond the MON program and
which would be supported by multiple NIH institutes,
perhaps through competitive ‘R’ grants. Importantly,
such support would also enable external model organism
experts to join the MON. We are advocating for support
for two distinct and important activities that will be carried out by the future MON: (1) providing rapid diagnosis
and (2) uncovering disease mechanisms. To expand further, Activity (1), the diagnosis of undiagnosed diseases
patients, involves using model organism experiments to
provide data that solve a medical mystery for a patient in
a timely manner; and Activity (2) the mechanistic understanding of previously undiagnosed diseases, includes
understanding the underlying biology of disease, using
rare diseases to understand common diseases, and preclinical identification and testing of therapeutics, which
is a more in-depth effort.
The key feature of the components and activities of
the current MOSC that distinguish it from other efforts
is that they target a particular undiagnosed patient to
provide timely information for diagnosis. In addition to
the defining contribution of the MOSC towards diagnosis (i.e., by providing evidence for or against pathogenicity of a specific variant), the future MON should also
make significant contributions towards understanding
the mechanistic basis for how a variant contributes to
disease pathophysiology. Although mechanistic studies
are not warranted in all cases, we strongly believe that
they are a powerful extension of MOSC diagnostic work
on new and unstudied disease genes. Moreover, MOSC
researchers generate animal models, acquire relevant
expertise, and are thus well-positioned to carry out such
mechanistic studies. In addition, because mechanistic
studies require time, expertise, and resources, investigators outside of the central MON team should have the
opportunity to drive these mechanistic studies. Given
the large number of known disease genes with unknown
mechanisms and expertise existing in laboratories outside of the MON, we envision that these future collaborations with experts in particular genes and pathways
would become part of a larger NIH effort to uncover
genetic disease mechanisms, in which the future MON
might be only one of the contributors. These investigator-driven mechanistic studies could be proposed using
any model organism or cellular or biochemical system,
and combinations thereof. We envision that these studies could be supported by specifically targeted R01, R03,
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or R21 mechanisms. The Coordinating Center of the
UDN has been exploring the benefit of providing funding
($150,000 per proposal) to recruit external researchers
with expertise in specific genes and pathways, and these
efforts have indeed facilitated the mechanistic understanding of disease mechanisms (https://undiagnosed.
hms.harvard.edu/research/funding-opportunities/). The
scientific justification for this dual set of goals (diagnosis
and mechanism) is that the work on diagnosis must progress in a timely manner to provide answers for patients
and their families. However, at the same time, more in
depth biological studies, albeit slower, must also be supported to translate these discoveries to therapeutics and
to common disease biology. Furthermore, even when
initial studies do not support the conclusion that nominated variants cause the particular patients’ diseases,
such negative results are valuable for the diagnostic mission because they prompt the clinical group to consider
other candidate genes and variants. In addition, this work
defines the functions of the investigated genes and variants, which might fit a different undiagnosed disease,
especially for previously unstudied genes.

Communication of the MON with other
NIH‑supported variant modeling efforts
Although the MOSC and future MON are unique frameworks within which to model human variants, we recognize a number of other ongoing efforts, both nationally
and internationally. Some NIH-funded efforts include the
Eunice Kennedy Shriver Intellectual and Developmental
Disabilities Research Centers (EKS-IDDRCs, NICHD),
the Rare and Atypical Diabetes Network (RADIANT,
NIDDK), the Accelerating Medicines Partnership Type 2
Diabetes Consortium (AMP TD2, NIDDK), and the Rare
Disease Clinical Research Network (RDCRN, NCATS).
We believe these groups would benefit from ongoing and
open communication with the future MON and the UDN
to ensure that patients are reviewed by the most appropriate group and to avoid duplication of efforts.
Consideration of Canadian and other international
model organism approaches for rare disease
The UDN MOSC is a centralized system of several laboratories with broad expertise, knowledge, and techniques
working collaboratively to solve many cases together.
An alternative model is for many individual laboratories with gene-specific expertise to work on particular
cases in which their genes of interest are the prime candidate of the undiagnosed condition. The Rare Diseases:
Models & Mechanisms Network (RDMM) in Canada is
a national network of model organism researchers and
clinicians that has been using this “distributive model” of
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functional studies for the past four years [78]. The UDN
MOSC signed a Memorandum of Understanding with
the RDMM in 2016 to exchange data, knowledge, and
expertise to support each other’s mission.
In the RDMM approach, clinicians from around the
country submit genes and variants of interest together
with the clinical description of the patient. A group of
clinicians that form the Clinical Advisory Committee
(CAC) reviews these submissions and assesses the quality of candidate variants. The CAC passes information
about appropriate gene variants to a group of biologists
and bioinformaticians that form the Scientific Advisory
Committee (SAC). Next, the SAC searches an internal database that contains information about model
organism researchers in Canada and their expertise, to
match the clinician and model organism researchers and
encourage collaboration. The clinician and model organism researcher can then make specific research plans and
co-submit a short research proposal back to the SAC.
The SAC reviews these applications and decides whether
or not to fund the project. Successful applicants receive
a CAD$25,000 grant for one year to pursue the project.
Interest in the project is extremely high: as of early 2020,
88% (543) of model organism laboratories across Canada
had enrolled in the database, and RDMM had funded
105 projects related to 87 genes. The network published
20 peer reviewed research articles including new disease gene discoveries, phenotypic expansions of known
disease genes, or mechanistic studies of known rare diseases. Due to its success in Canada, funding agencies in
Japan (IRUD/J-RDMM) (https://j-rdmm.org/indexEn.
html), Australia (AFGN) (https://www.functionalgenom
ics.org.au/), and Europe (Solve-RD) (http://solve-rd.eu/
rdmm-europe/) have developed RDMM-like networks
over the past two years.
Although the RDMM has been successful, there are
some limitations to this model, including potential difficulties in establishing a new collaboration for each disease gene studied and the relatively limited funds and
project period provided per gene. In addition, although
the RDMM system is very effective in studying variants
and genes for which some knowledge about their biological functions is available, genes without any in vivo
studies in any pre-existing model organism tend to be
left unstudied due to lack of a specific researcher with
expertise. The centralized MOSC system provides flexibility and resources for researchers to tackle these “genes
of unknown significance” by generating the first gene
knock-out lines and other reagents. We feel that the UDN
MOSC-like centralized facility that allows exploration of
variants in unstudied genes with a quick turnaround time
and RDMM-like matchmaking programs that involve a
number of scientists and experts in well-studied genes
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are complementary approaches. A dual funding system
such as the proposed MON that supports both types of
activities will likely maximize the benefit of clinicians,
basic scientists, as well as patients and family members
suffering from rare and undiagnosed conditions.

Summary and call to action
As the UDN reaches the end of its funding period from
the NIH Common Fund, we propose that multiple
NIH Institutes (such as NCATS, NEI, NHLBI, NHGRI,
NICHD, NIDCD, NIDDK, NIGMS, NINDS, ORIP and
others) work together to sustain and expand a competitive program for an ongoing UDN MOSC in the form of
a MON, because most undiagnosed patients have multiple organ systems affected. It is possible that grant funding to establish the MON or MON-like structure could
also be prioritized either through mechanisms such as
an entirely new Common Fund initiative that is more
focused on in vivo functional studies and mechanistic
research, or through specific efforts by different NIH
institutes. We argue that the work to sustain the MOSC
and its transformation into a larger MON is highly justified and that efforts to sustain a steady pace of high
impact gene discovery will pay off for rare and undiagnosed diseases, as well as impacting our understanding of
common diseases.
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